Divalproex sodium extended-release for the prophylaxis of migraine headache

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.9, 2003-09, pp. : 1573-1578

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Divalproex to Divalproex Extended Release Conversion

By Sandeep Dutta Ronald C. Reed

Clinical Drug Investigation, Vol. 24, Iss. 9, 2004-01 ,pp. : 495-508

Adis International

Access to resources Recommend Favorite

Development of Extended Release Divalproex Sodium Tablets Containing Hypdrophobic and Hydrophilic Matrix

Current Drug Delivery, Vol. 6, Iss. 3, 2009-07 ,pp. : 291-296

Bentham Science Publishers

Access to resources Recommend Favorite

Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs

By Sommerville K.W.

Clinical Drug Investigation, Vol. 23, Iss. 10, 2003-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite

Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial

Current Clinical Pharmacology, Vol. 12, Iss. 1, 2017-06 ,pp. : 55-59

Bentham Science Publishers

Access to resources Recommend Favorite

Extended-release (XR) venlafaxine appears effective in the prevention of migraine and CTTH

Inpharma, Vol. 1, Iss. 1255, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite